SEC61 translocon gamma subunit is correlated with glycolytic activity, epithelial mesenchymal transition and the immune suppressive phenotype of lung adenocarcinoma

• SEC61G expression is significantly correlated with glycolytic activity in LUAD, as evidenced by increased FDG uptake on PET/CT scans. • SEC61G promotes an immunosuppressive tumor microenvironment by negatively correlating with immune cell infiltration and modulating immune checkpoint genes. • Knockdown of SEC61G inhibits LUAD cell migration and downregulates key regulators of EMT and glycolysis, including HIF-1α and LDHA. • SEC61G emerges as a potential prognostic biomarker and therapeutic target for LUAD, with implications for predicting immunotherapeutic responses.